Stockreport

Guggenheim Initiates CG Oncology (CGON) Coverage with $90 PT, Highlights Bladder Cancer Therapeutic Cretostimogene [Yahoo! Finance]

CG Oncology, Inc. - Common stock  (CGON) 
PDF coverage of CG Oncology with a Buy rating and $90 price target. The firm believes that the non-muscle invasive bladder cancer market has lots of patients and pricing pow [Read more]